Centessa Reverses Lower Despite $5 Billion Narcolepsy Opportunity
In This Article:
Centessa has a potential blockbuster narcolepsy treatment on its hands, an analyst said Tuesday. But the biotech stock reversed into the red.
Oops, something went wrong
Centessa has a potential blockbuster narcolepsy treatment on its hands, an analyst said Tuesday. But the biotech stock reversed into the red.